Prognostic significance of the mad1l1 1673 g:a polymorphism in ovarian adenocarcinomas
Rev. invest. clín
; 72(6): 372-379, Nov.-Dec. 2020. tab, graf
Article
in En
| LILACS
| ID: biblio-1289732
Responsible library:
BR1.1
ABSTRACT
Abstract Background:
Ovarian cancer is the most lethal gynecologic cancer. Although most patients respond adequately to the first-line therapy, up to 85% experience a recurrence of disease, which carries a poor prognosis. Mitotic arrest deficiency 1 is a protein that helps in the assembly of the mitotic spindle assembly checkpoint by preventing anaphase until all chromatids are properly aligned. A single-nucleotide polymorphism in the MAD1L1 gene is prevalent in patients with advanced epithelial ovarian cancer and alters the way in which it responds to chemotherapy.Objective:
The objective of the study was to study the relationship between the rs1801368 polymorphism of MAD1L1 and prognosis of ovarian adenocarcinoma.Methods:
A total of 118 patients in whom the MAD1L1 gene was sequenced were analyzed using descriptive and comparative statistics.Results:
Patients carrying the wild-type genotype had a higher distribution of early-stage disease. Having a MAD1L1 polymorphic allele increased the risk of being non-sensitive to chemotherapy. The median disease-free survival for patients with the wild-type MAD1L1 was 46.93 months, compared to 10.4 months for patients with at least one polymorphic allele.Conclusions:
The rs1801368 polymorphism of MAD1L1 gene worsens prognosis in patients with ovarian adenocarcinoma. Traditional therapy for ovarian cancer might not be optimal in patients carrying this polymorphism.Key words
Full text:
1
Index:
LILACS
Main subject:
Ovarian Neoplasms
/
Adenocarcinoma
/
Cell Cycle Proteins
/
Polymorphism, Single Nucleotide
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
Language:
En
Journal:
Rev. invest. clín
Journal subject:
MEDICINA
Year:
2020
Type:
Article